Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
17.06
-1.31 (-7.13%)
Mar 31, 2025, 10:51 AM EDT - Market open
Immunovant Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Immunovant stock have an average target of 44.13, with a low estimate of 33 and a high estimate of 53. The average target predicts an increase of 158.68% from the current stock price of 17.06.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immunovant stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 6 | 5 |
| Buy | 6 | 5 | 6 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 11 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 20, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $38 → $33 | Strong Buy | Maintains | $38 → $33 | +93.43% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $51 | Strong Buy | Reiterates | $51 | +198.94% | Mar 19, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 10, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $46 → $44 | Strong Buy | Maintains | $46 → $44 | +157.91% | Feb 10, 2025 |
Financial Forecast
Revenue This Year
1.70B
from 814.35M
Increased by 108.88%
Revenue Next Year
n/a
from 1.70B
EPS This Year
-2.88
from -1.88
EPS Next Year
-3.15
from -2.88
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 65.1M | 150.2M | |||
| Avg | n/a | 7.9M | 62.2M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | 1,799.4% | |||
| Avg | - | - | 687.0% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.56 | -2.57 | -2.88 | |||
| Avg | -2.88 | -3.15 | -3.34 | |||
| Low | -3.03 | -3.52 | -3.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.